U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07142291) titled 'Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS' on Aug. 19.
Brief Summary: The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Amyotrophi...